Form 4 for CLB Core Laboratories Inc. /DE/
Accepted 2024-01-03 00:00:00 ET · period of report 2023-12-31 · accession 0000950170-24-001245 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-01-03 | 2023-12-31 | CLB | Daniels Kevin | CAO, Treas | M - OptEx | $0.00 | +7,200 | 15.9K | +82% | $0 |
| D | 2024-01-03 | 2023-12-31 | CLB | Daniels Kevin | CAO, Treas | F - Tax | $17.66 | -2,769 | 13.2K | -17% | -$48.9K |
| D | 2024-01-03 | 2023-12-31 | CLB | Daniels Kevin | CAO, Treas | M - OptEx | $0.00 | -7,200 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-12-31 | M | A | 7,200 | $0.00 | 15,949 | D | — | — | |
| 2 | Common | Common Stock | 2023-12-31 | F | D | 2,769 | $17.66 | 13,180 | D | — | — | |
| 3 | Derivative | Performance Shares | 2023-12-31 | M | D | 7,200 | $0.00 | 0 | D | $0.00 · — to — | 7,200 Common Stock | (F1) These shares were awarded as restricted performance shares in February 2021, as disclosed in the Reporting Person's Form 4 filing on February 19, 2021. All requirements for 100% vesting have been met and thus the restricted shares vested on Decmeber 31, 2023 at the conclusion of the performance period. |